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Dr. Thomas E. Starzl is Professor of Surgery and Director of the Transplantation Institute at the University of 
Pittsburgh School of Medicine. He is an internationally famed 
contributor in the field of transplantation and is currently 
pursuing studies on xenotransplantation, both in the experi-
mental laboratory and in a recent clinical case. In this Resi-
dents' Edition of Annals of Surgery, he has provided an 
extraordinary commentary on the future of xenotransplanta-
tion. His article will predictably be widely read and acclaimed 
by surgical residents across the nation. 
o Dr. Starzl is a native of Iowa and attended Westminster 
College, where he was later selected for the Alumni Achieve-
ment Award. At Northwestern University, he received both a 
Ph.D. and a medical degree and was elected to Alpha Omega 
Alpha. He obtained his residency training at Johns Hopkins 
University, under the late Alfred Blalock, and also at the 
University of Miami. Mter he completed his surgical residency, 
he was appointed to the faculty in the Department of Surgery 
at Northwestern University. In 1964, he became Professor and 
Chairman of the Department of Surgery at the University of 
Colorado, where he rapidly built a distinguished clinical and 
investigative program in the field of transplantation. He is in 
large part responsible for the commonly held view that trans-
plantation is medicine's miracle of the twentieth century. 
Throughout his career, Dr. Starzl has been the prime leader 
and is appropriately given primary credit for successful trans-
plantation of the liver. He rapidly became aware of the basic 
studies of Medawar, Billingham, Dempster, and others who 
provided much of the original fundamental work in the field. 
Within a short time, he exchanged many ideas with Hume, 
Murray, Egdahl, Mannick, and Moore, each of whom was also 
a pioneer. 
o It is interesting to note that early in his appointment to the 
faculty at Northwestern University, Dr. Starzl applied for a 
National Institutes of Health research grant in transplantation 
and began canine hepatectomy experiments, followed by the 
first experimental transplantation, which was performed in 
July 1958. At that time, he was also named a Markle Scholar, 
which is a very prestigious and highly competitive academic 
award. 
o Always appropriately aggressive, Dr. Starzl performed the 
first human kidney transplant 3 months after he arrived at the 
University of Colorado on March 27,1962. Twenty-nine years 
later, the patient was still alive. On March 1, 1963, he made 
his first attempt at a human liver replacement, and he estab-
lished an ideal transplant laboratory at the Veterans Admini-
stration Hospital in Denver. There he began a committed 
approach in making a series of fundamental contributions in 
transplantation. 
o The advent of cyclosporine greatly extended Dr. Starzl's 
clinical program, but the side effects were recognized and 
attempts were made to prevent them. The macrolide antibiotic 
FK 506 was discovered in 1984, and Dr. Stanl rapidly 
assumed the leadership position in the study and clinical 
application of this agent, which has greatly extended allograft 
survival. 
o It is astonishing to review the enormous productivity of 
Thomas Starzl. He has authored 1470 scientific articles, has 
written 177 chapters in textbooks, is the author of four books 
of his own, and has made nearly 1000 scientific presentations 
at major national and international meetings. 
o PJ, would be predicted from his many contributions, Tho-
mas Starzl has received many national and international 
honors. He was the Founding President of the American 
Society of Transplant Surgeons and has served as Vice Presi· 
dent and President of the International Transplantation Soci· 
ety. He was elected Colorado Man of the Year and received a 
similar award from the city of Pittsburgh. He received the 
Sheen Award of the American College of Surgeons, the 
Alumni Medal of Northwestern University, the Bigelow Medal 
of the Boston Surgical Society, and the William Beaumont 
Prize in Gastroenterology. The American Surgical k.sociation 
bestowed upon him its prestigious and rarely awarded Medal· 
lion for Scientific Achievemenl In 1986, he was appointed 
Distinguished Service Professor of Health Sciences at the 
University of Pittsburgh. He has been made an Honorary 
Fellow of the Royal College of Surgeons of England, the Royal 
X enotransplantation (heterotransplantation) exemplifies how history repeats itself. Attempts at whole organ 
transplantation were made between 1906 and 1923 using pig, 
sheep, goat, and subhuman primate kidney donors.' The first 
of these efforts were in France and Germany," and in some 
cases, the blood vessels coming to and leaving these organs 
were sewn to recipient blood vessels in much the same way 
as today. None of the kidneys functioned for long, if at all, and 
the human recipients died anywhere from a few hours to 9 
days later. 
College of Surgeons in Ireland, and the Royal College of 
Physicians and Surgeons of Glasgow. He is also an honorary 
member of the PJ,ian Surgical k.sociation and Elu associe 
etranger Academie Nationale de Medecine in France. 
o In his commentary in this Residents' Edition, Dr. Starzl 
carefully assesses the future of xenotransplantation by sum· 
marizing the clinical and investigative work previously done 
in this field and reviewing the work currently in progress. 
Convinced from the studies that he and his colleagues had 
conducted in the field of xenotransplantation, on June 28, 
1992, he transplanted a baboon liver into a patient with liver 
failure due to type B hepatitis. One can scarcely imagine a 
more authoritative review of this important and timely subject. 
Moreover, the fun meaning of Dr. Starzl's contributions are 
best understood by simultaneous reading of his recently 
published autobiography, The Puzzle People: Memoirs of a 
Transplant Surgeon. This masterwork is an objective ap-
praisal of his many contributions to clinical investigative 
surgery, especially in the field of transplantation, and provides 
abundant evidence of the many reasons his name is already 
deeply carved into the stone of surgical history. 
David C. Sabiston, Jr., M.D., Editor 
The Chimpanzee Donor 
o The demonstration in 1962 and 1963 that renal allotrans-
plantation was routinely feasible with azathioprine-predni. 
sone therapy' created an organ shortage crisis and 
reawakened interest in xenotransplantation. Cadaveric brain 
death was 5 years in the future, the number of living donors 
was limited, and renal dialysis programs as an option were few 
in number. Desperate potential kidney recipients were piling 
up faster than places could be found for them in the few 
existing dialysis facilities. 
o As the crisis deepened, xenotransplantation was re-ex-
plored. On February 16, 1963, Dr. Claude Hitchcock of the 
Hennepin County Hospital, in Minneapolis, transplanted the 
kidney of a baboon to a 65-year-old woman. The organ 
functioned for 4 days before its artery clotted.5 The case was 
not made public until it was learned later in 1963 of a far more 
encouraging experience by Dr. Keith Reemtsma of Tulane 
University using the closer-to-human chimpanzee donor.6 One 
of Reemtsma's first six chimpanzee kidney grafts functioned 
for 9 months. The second longest survival time was 2 months, 
but in subsequent trials, neither of these longevity landmarks 
could be reached again. Reemtsma also transplanted the liver 
of a Rhesus monkey, and it was fiercely rejected. 
o Later, Cortesini of Rome' and probably others who did not 
report their cases accumulated chimpanzee xenotransplanta-
tion experience that generally confirmed Reemtsma's find-
ings. Hardy attempted a chimpanzee-to-human heart 
transplant that failed intraoperatively,! and liver transplanta-
tion with chimpanzee donors was attempted three times by 
us, 19 or more years ago, with a maximum survival time of 9 
days.' The histopathologic findings at autopsy were not distin-
guishable from those in hepatic allografts at comparable 
times. No further attempts at chimpanzee-to-human 
xenotransplantation have been made using modem immuno-
suppression (with cyclosporine or FK 506), and future at-
tempts are not likely because of the endangered status of these 
animals. 
The Baboon Donor 
D Beginning with Hitchcock's case,' much also was learned 
about baboon-to-human transplantation during this period. In 
December 1963 and January 1964, six additional patients 
were given baboon kidneys at the University of Colorado.,o,ll 
All of the organs functioned promptly and maintained dialy-
sis-free life for 10 to 60 days. However, the necessary doses 
of azathioprine and prednisone were very high, and eventu-
ally, the grafts were rejected. The rejection was midway in 
severity between that of the chimpanzee kidney and that of 
the Rhesus monkey kidney, but it was not qualitively different 
than had been observed in allografts.'z The same events were 
recapitulated two decades later in the Baby Fae baboon-to-hu-
man heart transplantation, in spite of heavy cyclosporine-ster-
oid immunosuppression. IJ It was clear that the use of baboon 
organs would have to wait for better and possibly fundamen-
tally different immunosuppression. The more distant phyloge-
netic separation of the baboon from the human compared with 
the chimpanzee-human relationship was reflected in the pa-
thologic findings in these xenografts. Spotty necrosis or 
uneven regional infarctions developed in all of the baboon 
kidneys (and Baby Fae's heart). It was unfortunate that there 
were not better humoral antibody studies in the early days. It 
already was known that anti-graft ABO isoaggIutinins could 
cause hyperacute rejection,'· but the use of serologic tech-
niques beyond this for the detection of preformed anti-graft 
antibodies had not yet been applied in transplantation. For 
example, the role of Iymphocytotoxic antibodies as a cause for 
hyperacute humoral allograft rejection was not recognized 
until 1965.15,," 
o Nevertheless, in the 1963 baboon cases, we showed that 
heterospecific antibodies bound to the grafts by showing titer 
declines in the patients' sera with confirmatory electron 
micographic studies.'o.ll The pathologist K. A. Porter con-
cluded that 
"in the resulting [xenograft] rejection process, cellular 
infiltration and peritubular capillary destruction are promi-
nent early pathologic features, but by nine days the vascu-
lonecrotic element is marked. There is circumstantial 
evidence to suggest that, whereas the peritubular capillary 
damage is mediated by cell-bound antibody, the fibrinoid 
necrotic vascular lesions are caused by circulating anti-
body."" 
Interdiction of Antibodies 
o The antibody (humoral) component of rejection has been 
the central issue of xenotransplantation since that time."'" 
The interrelation of all performed anti-allograft and anti-
xenograft antibody syndromes was recognized from the out-
set, »22 and in fact, xenograft models using disparate donor and 
recipient species have been used to evaluate treatment strate-
gies that are designed to prevent the hyperacute rejection of 
ABO-incompatible allografts or allografts transplanted to sen-
sitized human recipients. The justifiable assumption has been 
that the mechanism of antibody destruction of allografts and 
xenografts is by the same process. Techniques to prevent 
humoral rejection have been summarized elsewhere." They 
include plasmapheresis; antibody removal with a Staphylococ-
cus A column; transplantation of serial grafts to reduce the 
antibody titer; infusion of the chelating agent citrate, which 
is an anticoagulant and an effective preventer of complement 
activation; and the use of prostanoids and other inhibitors of 
the inflammatory response. 
o Of these approaches, it is interesting that one of the most 
promising, prostaglandin therapy, has received the least atten-
tion. Prostaglandin compounds can mitigate the xenograft 
rejection of hamster-to-rat, 23.Z4 cat-tooog, 25 and pig-tooog" 
organs. Quagliata et al. published evidence in 1973 that 
prostaglandin had a specific effect on B cells and concluded 
that such drugs would be valuable for xenotransplantation,27 
o Most importantly, it was shown recently that PGE, and a 
short course of high-dose steroids as part of FK 506-based 
drug cocktails permitted the transplantation of liver allografts 
to patients with Iymphocytotoxic antibodies, with no increased 
risk of immediate antibody rejection. The long-term prognosis 
in these high-risk patients was converted to the same as that 
of crossmatch-negative recipients.- This discovery was one of 
the prime justifications for the recent baboon-to-human liver 
xenotransplantation trial. Although prostaglandins are inher-
ently but weakly immunosuppressive,211 their unique value for 
xenografting was via the antibody arm of the xenograft 
reaction, possibly by modifying the cytokine inflammatory 
response.24,30 In addition to their immunosuppressive effect, 
prostaglandins also reduce the nephrotoxicity of cy-
closporine31.32 and FK 506.21.33 This latter property has made us 
recommend PGE1-along with FK 506 plus prednisone and 
PGE1-as one of the three constituents of our current immu-
nosuppressive cocktail for all liver recipients.33 This was the 
baseline treatment for a recent human recipient of a baboon 
liver. 
The Anti-metabolite Drugs 
o Although the duality of humoral and cellular mechanisms 
of xenograft rejection has become common knowledge, the 
antibody component has been refractory to treatment in many 
experimental models, even with the use of drug cocktails that 
include PGEl- For example, prostaglandin was effective only 
during its constant infusion at high doses in the cat-tCKiog 
experiments,25 and in the hamster-to-rat model. its efficacy is 
even more limited (personal unpublished observations).23.:U A 
hamster organ is confronted in the rat recipient by a moderate 
titer (1: 16 to 1:32) of preformed heterospecific cytotoxic 
antibodies of the IgM class and, subsequently, by a rapidly 
gathering antibody storm. The antibodies destroy abdominally 
placed cardiac grafts within 3 days in untreated recipients, 
before there is a trace histopathologically of immunocyte 
infiltration. Hamster livers are rejected in 7 days by combined 
ceIJular and humoral mechanisms. The antibody component 
is reflected in the occlusive endotheliolitis of the entire graft 
vasculature. 
o FK 506 prevents T cell activation and cytokine secretion. 
By itself, in doses of 2 mg/kg/day, FK 506 prolonged heart 
xenograft survival by only 1 day. Mter liver transplantation, 
it allowed survival of half of the liver recipients for longer than 
• Table 1. Graft Survival 
Type of Graft Group Treatment + 
Heart 1 None 
2 FK506 
3 RS01443 
4 BQR 
5 Cyclophosphamide 
6 Cyclophosphamide 
Liver 7 None 
8 FK506 
9 RS01443 
10 BQR 
11 Cyclophosphamide 
12 Cyclophosphamide 
30 days (Table 1), but none survived as long as 100 days. 
Monotherapy with either of two experimental "antiprolifera-
tive" drugs that suppress purine (RS 61443) or pyrimidine 
(Brequinar) ribonucleotide synthesis tripled or quadrupled 
the survival times of hamster-to-rat xenografts but did not 
permit consistent chronic survival. However, when either of 
the two anti-metabolite drugs or the conventional anti-cancer 
drug cyclophosphamide was added to FK 506 for the first 2 
postoperative weeks, indefinite survival under continued ad-
ministration of FK 506 alone became routinely possible after 
either heart or liver transplantation.34 The finding that a single 
large dose of cyclophosphamide 10 days before transplanta-
tion permitted nearly 10096 success after either heart or liver 
transplantation with daily administration of FK 506 was 
particularly noteworthy (Table 1). 
o The conclusion from these studies by Murase et al34 was 
that prevention or mitigation of heterospecific antibody rejec-
tion by interdiction of the B cell proliferative response with a 
variety of anti-metabolite drugs for a surprisingly short period 
after transplantation or even beforehand was the essential first 
step to successful xenotransplantation. Thereafter, the poten-
tial of continuous therapy with T cell-directed immunosup-
pressants such as FK 506 was unmasked. Hasan et al35 showed 
the same kind of extraordinary synergism between cy-
closporine and cyclophosphamide. Such combination therapy 
was predicted to be clinically applicable as long as the humoral 
antibodies did not act so rapidly that they caused hyperacute 
rejection in a few minutes or hours. This condition was known 
from the earlier clinical experience to pertain in the baboon-
Without FK 506 
n Survival >30 days 
6 0 
6 0 
4 0 
6 
5 0 
5 0 
8 0 
10 5 
ND ND 
7 
ND ND 
5 0 
With FK 506 
n Survival >30 days 
6 
5 
5 
5 
10 
7 
10 
15 
5 
5 
5 
5 
9 
6 
9 
12 
• These experiments are a fraction of those performed. A full account of this work as well as the testing of numerous other compounds is 
provided in ref. 34' 
+ Daily dose (mg/kg): FK 506, 2.0 x 6, 1.0 x 25 (heart) or 1.0 x 30 (liver), and 0.5 on alternate days thereafter; RSOI443, 20.0 x 15 (14) 
starting day before Tx (heart) or day of Tx (liver); BQR, 4.0 x 3 and 3.0 x 12 starting day before Tx (heart) or 3.0 x 14 starting day of Tx 
(liver); cyclophosphamide, 7.5 x 15 (14) starting day before Tx (heart) or day of Tx (liver), except groups 6 and 12, to which one dose of 
80 mg was given 10 days before operation. 
Animals alive at 30 days survived as long as FK 506 was continued out of 100 days no matter what the adjuvant induction drug. 
to-human species combination."13 The choice of cyclophos-
phamide as the anti-metabolite drug for the eventual clinical 
cocktail in preference to several other agents with the same 
general "anti-proliferative" mechanism34 hinged on this drug's 
effectiveness, the fact that it was an accepted drug in the 
formulary, and the fact that we had previously used it exten-
sively as a conventional immunosuppressant in the era pre-
ceding cyclosporine.30,37 
The Liver aa a Xenograft 
Immunologic Advantages 
o In the research with hamster-to-rat xenotransplantation 
before the start of clinical trials, two organs were used for 
screening.34 One was the heart, which is considered immu-
nologically "difficult" because of its rejection within 3 days in 
unmodified recipients. In contrast, hamster liver xenografts 
were not rejected by rats until 7 days after transplantation.34 
As a general principle, livers have an immunologic advantage 
relative to other organs, including a greater ease of inducing 
their acceptance as allografts- or xenografts" after a limited 
course of immunosupppression or, in swineC2 and some rat 
strain combinations, with no treatment at all. In addition, the 
hepatic allograft and xenograft are relatively resistant to the 
preformed antigraft antibodies that cause hyperacute rejec-
tion of the kidney and heart "K~ Another quality of the liver 
is its unusual ability to induce a state of unresponsiveness to 
other tissues and organs transplanted concomitantly or sub-
sequently from the donor or donor strain .. ·•7 and even shield 
these organs from the hyperacute rejection caused by pre-
formed allospecificCd or xenospecific49 anti-donor antibodies. 
Thus, the liver was the organ predicted to have the best 
prognosis for clinical xenotransplantation. It also was an 
organ for which there is great need, because unlike the kidney, 
there is no alternative of artificial organ support, and unlike 
the heart, there is no realistic prospect of developing an 
artificial alternative. 
Metabolic Questions 
o In spite of its immunologic advantages, serious further 
questions were raised about liver xenografts. After hepatic 
transplantation, liver allografts continue to produce donor-
phenotype proteins and other synthetic products, allowing 
this operation to be used to correct numerous liver-based 
inborn errors of metabolism.50 Because the same retention of 
donor specificity was expected after successful hepatic 
xenotransplantation, the consequence of successfully engraft-
ing a liver xenograft could be the imposition on the recipient 
of an interspecies metabolic incompatibility. This would be 
equivalent to transplanting an inborn error of metabolism. 
o We examined this possibility in the hamster-to-rat liver 
replacement model by studying clotting factors known to be 
synthesized in the liver as metabolic markers. Although ham-
sters and rats are both rodents, the phylogenetic distance by 
paleontologic and genetic evidence has been estimated at 15 
to 40 million years.51 Results of clotting tests showed great 
disparity between the two species, the most striking being 
protein C, which was always present in normal hamsters but 
was undetectable in nonnal rats. In rats that had been 
transplanted with hamster livers, the coagulation profile of 
the rat recipient quickly changed to that of the hamster range 
of values.52 Neither bleeding nor clotting was observed clini-
cally more than after rat liver allotransplantation. 
o The replacement of other metabolic moieties was obvious; 
for example, circulating hamster albumin was found in rat 
recipients of hamster livers.52 These results and the results of 
other metabolic studies suggested that the donor-specific 
products of hepatic synthesis in significantly disparate species 
combinations such as hamster to rat did not present an 
insurmountable or even an important metabolic barrier to 
hepatic xenotransplantation. 
Beyond the Baboon 
o Generally speaking, the humoral antibody barrier becomes 
more extreme roughly in proportion to the degree of species 
disparity, so that with widely divergent species, humoral 
(hyperacute) rejection is expected within a few minutesY-19,5J..17 
However, trial and error has been the only way to rise above 
speculation with any given animal-to-human combination, 
providing an example that "all triumphs in medicine are the 
forgotten sorrows of past days."53 Thus, the earlier failed 
xenotransplantation efforts"13 yielded information about the 
extent of the human barrier to the baboon species that was 
the background for the 1992 trial. 
o Because the pig is often mentioned as a possible clinical 
organ donor, it is important to recount an unreported attempt 
by Rene Kuss, the pioneer French transplant surgeon, at 
pig-to-human renal transplantation in the early 1960s under 
azathioprine and prednisone administration (personal conver-
sation with Professor Kuss of Paris and Dr. Jacques Poisson 
of Nice, November 1990). The kidney functioned well for 
approximately 30 minutes, but then it underwent hyperacute 
rejection. The dominant finding was widespread thrombosis 
of the microvasculature, concentrated in the venules. Kuss' 
willingness to share this experience almost three decades later 
was important because this kind of vitally needed information 
would be difficult to obtain in the clinical research climate of 
today. As a donor, the pig will not be easy. Platt et aLso have 
studied the details of the hyperacute rejection seen in discor-
dant species combinations, with particular emphasis on the 
complement-mediated injury to the graft vascular endothelial 
cells. Efforts to definitively prevent the resulting destruction 
of the vasculature have been uniformly unsuccessful to date. 
Consequently, the use of genetic engineering to humanize the 
organ blood supply endothelium in pigs or other discordant 
species may be necessary before there is hope of clinical 
application. This strategy and others have been discussed in 
recent reviews and editorials.50,57,59 
Cell Migration, Repopulation, and Chimerism 
o After breaking through the antibody barrier, the process 
of xenograft acceptance involves the cell migration and con-
sequent systemic chimerism that were recently delineated in 
humans after hepatic and other allotransplantationK~O One 
hundred days after hamster-to-ratheart or liver xenotransplan-
Hamster 17 18 46 
Is mL 115 mLlls mL cL T H Sk I I 5 mL cL T 
: 
.. 
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Fill. 1. For molecular detection of chimerism in the rat tissues after xenotransplantation of hamster hearts or livers, 1 ~g of genomic DNA 
extracted from each tissue was polymerase chain reaction amplified for 30 cycles with hamster-specific oligonucleotides. One fifth of the volume 
of each reaction was size separated on an agarose gel, transferred on a nylon membrane (hybond-N+, Amersham, Arlington Heights, IL), and 
probed with a hamster hypoxantine phosphoribosyltransferase exon 9 probe. The experiments were performed by Drs. Norlko Murase and 
Luis Valdivia, and the polymerase chain reaction examinations were done by Drs. Massimo Trucco and Roberto Giorda. S, spleen; mL, 
mesenteric lymph node; cL, cervical lymph node; T, thymus; H, heart; Sk, skin. Rats 1, 17, 18,46, 198, and 238 received hamster livers 104 
to 141 days previously; rats 19,24, and 31 received hearts 111 to 135 days earlier. 
tation, we showed that rat recipient dendritic and lymphoid 
cells migrated into hamster heart or liver xenografts, where 
they become part of genetically composite transplants.63 The 
displaced cells going out from the xenografts can be detected 
in recipient tissues with polyclonal anti-hamster antisera and 
confirmed with polymerase chain reaction techniques (Fig. 1). 
In these experiments, the chimerism was most obvious and 
frequent in the spleen or heart of the rat recipients. It was 
unequivocal after liver transplantation and occurred at a low 
level after heart transplantation. This means that successful 
clinical xenotransplantation must be visualized along the 
same lines of donor-recipient cellular intimacy, which we 
perceive to be the fundamental means of xenograft and 
allograft acceptance (Fig. 2). 
Peer Review 
o This background provided our personal knowledge base 
for xenotransplantation. Convinced from our own work by 
November 1991 that baboon-to-human liver grafting could be 
performed successfully, we notified officials at the National 
Institute of Diabetes and Digestive and Kidney Diseases of the 
National Institutes of Health (Drs. Jay Hoofnagle and Philip 
Gordon), the Food and Drug Administration (Drs. Ron lieber-
man and Gregory Burke), and the head of the Department of 
Health and Human Services (Dr. Louis Sullivan) of this 
conclusion. The next 8 months were spent in discussions with 
members of these government agencies, the University of 
Pittsburgh Institutional Review Board, a variety of ethics 
committees and, toward the end, members of Congress who 
have had a special interest in health care problems. In March 
1992, an outside peer review board of six members from 
centers in the United States and Europe (chaired by Dr. Keith 
Reemtsma of Columbia University, New York) met in Pitts.. 
• I 
Fig. 2. Schematic view of the kind of chimerism that is documented 
in Figure 1. We believe that this mixed chimerism is necessary for 
either allograft or xenograft acceptance. 
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Fig. 3. Course of the patient after receipt of baboon liver. PGE, prostaglandin E; SN, solumedrol (methylprednisolone). 
burgh with the University Institutional Review Board to 
evaluate the evidence, the proposal to go forward clinically, 
and the informed consent. They recommended unanimously 
that the trial proceed, providing that certain nonsubstantive 
changes were made or that ancillary experimental data be 
acquired. These recommendations or suggestions were fol-
lowed. 
o A baboon-to-human liver transplantation was scheduled on 
June 28, 1992. Consensus was reached with all parties con-
sulted. At 5:00 A.M., Jeffrey Romoff (President of the Univer-
sity Medical Center), Professor Luigi Fassati of Milan (one of 
our European collaborators), and I flew to Washington to 
address a joint meeting of the National Institute of Allergy and 
Infectious Diseases of the National Institutes of Health and 
the New York Academy of Sciences. There, at the end of an 
account of the supporting research, I announced that: 
..the decision was made to proceed with the baboon-to-hu-
man liver transplantation that will take place there after 
our return this afternoon. There is no more appropriate 
forum to make these plans known in advance and to 
Fig. 4. Transhepatic cholangiogram on postoperative day 6, several 
minutes after the injection of 5 mL dye. Although the initial reading 
was normal, with no obvious obstruction at the anastomosis (lower 
arrow), note the fullness of the duct system and the irregularity of 
the sludge-filled peripheral ducts (upper arrows). At autopsy 10 days 
later, the duct system was found to be filled with inspissated sludge. 
provide their justifications as I have tried to do than at this 
remarkable meeting of scientists." 
o We returned immediately to Pittsburgh, where the opera-
tion began 
Baboon-to-Human Liver Transplantation 
o The donor and recipient operations were performed in 
Pittsburgh on June 28, 1992, by Drs. Andreas Tzakis, John 
Fung, and Satoru Todo, with subsequent intensive care pr~ 
vided by Drs. Ignazio R. Marino and Howard R. Doyle. The 
recipient was a 35-year-old man with end-stage chronic active 
hepatitis caused by B virus that is thought incapable of 
infecting the baboon liver." Although he also was a carrier of 
the human immune deficiency virus (HIV), he was immune 
competent as judged by normal responsiveness of his lymph~ 
cytes to phytohemaggJutin, concavalin A, baboon lymphocyte 
stimulation, and third-party lymphocyte stimulation. 
o The four-drug immunosuppressive cocktail of FK 506, 
prednisone, PGEI, and cyclophosphamide (Fig. 3) was remark-
ably effective in preventing the fierce cellular rejection seen 
in previous baboon-t~human renal or heart xenografts under 
the administration of azathioprine and prednisone or cy-
c1osporine and prednisone."'3 Most importantly, the deadly 
occlusive endotheliolitis of xenospecific humoral rejection 
was completely avoided. Preformed lymphocytotoxic anti-ba-
boon antibodies of class IgM that were present in low titer 
preoperatively in the recipient serum did not increase after 
transplantation, and no circulating IgG antibodies ever were 
measurable. A postperfusion biopsy of the baboon liver from 
a 53-pound donor showed neutrophils in the sinusoids, but at 
a time when there was no clinical evidence of hyperacute 
rejection. Diffuse IgM and IgG antibodies shown in the 
xenograft biopsy specimen with immunofluorescence at 12 
days had largely disappeared by 24 days. 
o Minor periportal cellular infiltrates were seen in the 12-, 
24-, and 65.Qay biopsy specimens, but the patient had continu-
ously good liver function, except for jaundice, which recurred 
after 8 weeks. Findings of a diagnostic cholangiogram ob-
tained on postoperative day 61 initially were interpreted as 
normal (Fig. 4). However, the procedure precipitated a septic 
crisis, including disseminated intravascular coagulation and 
acute hyperbilirubinemia, followed by death on day 70 that 
resulted from a subarachhnoid hemorrhage that was thought 
to have come from aspergillus erosion of a cerebral artery. At 
autopsy, the xenograft showed only minimal findings of rejec-
tion. The principal abnormalies were intrahepatic biliary 
sludge, rupture of the ducts, and consequent bile leakage into 
the tissue (Fig. 5). There was virtually no elevation in the 
results of tests of hepatocyte injury, nor was there any 
diminution of synthetic function up to the morning of death. 
Fig. 5. Xenograft biopsy at 65 days, 5 days before death. There was 
absence of rejection. The dominant finding was cholestasis. (A, top) 
A bile lake occupies the central part of the field. Note the absence of 
most of the epithelium. (8, bottom) Intrahepatic ducts showing 
discontinuity of epithelium at sites of rupture. HOlE, original 
magnification x250. 
o The primary explanation for the fatal outcome was unrec-
ognized partial biliary obstruction with bacterial translocation 
through the compromised ducts. Ironically, the repeated 
failure to diagnosis this same complication impeded the early 
development of liver allotransplantation more than any other 
single factor.- Then, as in the current case, the elevated 
levels of alkaline phosphatase and other cannulicular enzymes 
and, ultimately, the jaundice caused by biliary stasis were 
systematically ascribed to rejection and treated as such in spite 
of the lack of histopathologic support for this diagnosis. In 
future trials, biliary stasis should be preventable by stenting 
the biliary anastomosis with an exteriorized catheter that also 
can be used to perform cholangiography postoperatively or to 
irrigate at will. 
o Aside from stimulating improvements in surgical manage-
ment, the candid acknowledgement that failure in this case 
was fundamentally technical and, thus, avoidable allows easy 
interpretation of the other observations that were generally 
encouraging and supportive of further cautious trials. With a 
cocktail that included nonmyelotoxic quantities of Cytoxan 
(cyclophosphamide), the doses of conventional immunosup-
pressive agents were not remarkably different from those used 
for allotransplantation. How much this patient's HIV carrier 
status contributed to the ease and completeness with which 
the xenograft rejection was controlled and to the complex 
terminal sepsis is open to speculation. However, because the 
patient was immunocompetent at the outset, the principal 
immunologic depression postoperatively was clearly iatro-
genic, not derivative from HIV. 
o In addition, the recipient appeared to have started the 
transformation to the same state of mixed chimerism observed 
in rats after their receipt of hamster livers. Thirty-five days 
after the transplantation, baboon DNA blood chimerism was 
identified in the patient's blood with baboon chorionic gona-
dotropin B subunit genes." At autopsy, chimerism was shown 
unequivocally in the lungs, heart, skin, lymph nodes, and 
numerous other host tissues.7• The extent of the chimerism 
was far greater than that seen in the hamster-to-rat model and 
has emphasized the degree of donor-recipient cellular inti-
macy that can be expected with successful xenotransplanta-
tion (Fig. 6). 
o An additional question largely answered by this single case 
was whether elaboration by a liver xenograft of donor pheno-
type proteins and other synthetic products would in essence 
impose on the recipient as serious or lethal incompatibility of 
metabolism. As had been predicted from the hamster-to-guinea 
pig experience,52 the serum protein pattern of the recipient 
was rapidly "baboonized," including the albumin, C3 comple-
ment, and other moieties involved in either immune reactions 
or blood coagulation.Of The fall of the patient's serum uric acid 
level postoperatively to the nearly undetectable level that is 
normal for the baboon was another particularly dramatic 
demonstration of the recreation by the xenograft of its own 
chemical environment with no apparent adverse effects. Such 
observations support the conclusion from the hamster-to-rat 
experiments that donor-specific products of hepatic synthesis 
do not present a fundamental barrier to liver xenotransplan-
tation. 
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Fig. 6. The nature of chimerism 70 days after clinical 
xenotransplantation. 
o Death at 70 days occurred too soon to allow a conclusion 
that the transplanted baboon liver could successfully resist 
infection with hepatitis B virus. However, there was no evi-
dence of the hepatitis B virus surface or core antigen in the 
transplant at autopsy, after a time in which infection of 
allografts has been frequently recorded,?1 
Mtermath 
o On Friday, September 11, 1992,5 days after the patient's 
death, a meeting organized by Dr. Keith Reemtsma of New 
York City was convened under the sponsorship of the New 
York Academy of Medicine. A clinicopathologic analysis of this 
crucial case was provided by the xenotransplantation teams 
from the University of Pittsburgh and Columbia University, 
with discussion by other experts from four European and 
numerous American centers. The consensus of the partici-
pants was that cautious further xenotransplantations were 
justified with baboon donors, but with emphasis on the 
extremely experimental nature of these trials and with a 
commitment to open disclosure in every case. 
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